Engineered Immune Cells Show Prolonged Cancer & HIV Fight | Einstein Medicine Research

A new approach to engineering immune cells offers a significant step forward in the fight against both cancer, and HIV. Researchers at Albert Einstein College of Medicine have developed a method to extend the lifespan and effectiveness of CAR-T cells – a type of immunotherapy – providing more sustained control of cancers and suppression of HIV infection in preclinical models. This addresses a key challenge in immunotherapy: ensuring these engineered cells remain active long enough to deliver a lasting therapeutic benefit.

Boosting Immune Cell Endurance

The research, published in Science Advances, centers on a “multi-cytokine scaffold” designed to support and prolong the function of CAR-T cells. CAR-T cell therapy involves extracting a patient’s T cells (a type of immune cell), genetically modifying them to recognize and attack cancer cells or virus-infected cells, and then infusing them back into the patient. Although CAR-T therapy has shown remarkable success in treating certain blood cancers, its effectiveness against solid tumors and chronic viral infections like HIV has been limited by the cells’ tendency to “burn out” quickly.

The Einstein team’s innovation tackles this problem by providing the CAR-T cells with a continuous supply of essential survival signals. Cytokines are signaling molecules that play a crucial role in regulating the immune system. By incorporating multiple cytokines into the scaffold surrounding the CAR-T cells, the researchers created a microenvironment that promotes their persistence and activity. This approach, compared to existing methods, generates longer-lasting immune cells.

CAR-T Therapy and HIV: A Complex Landscape

The potential application of this technology to HIV is particularly noteworthy. Currently, people living with HIV rely on antiretroviral therapy (ART) to manage the virus, but ART is not a cure. It prevents HIV from replicating, but it doesn’t eliminate the virus entirely, which can persist in a latent state within immune cells. Stopping ART leads to viral rebound. The Einstein-Rockefeller-CUNY Center for AIDS Research, where some of this work originated, has been at the forefront of efforts to find a functional cure for HIV. Learn more about their work here.

In 2021, scientists at Albert Einstein College of Medicine announced a separate strategy involving proteins designed to stimulate the immune system’s CD8+ “killer” T cells to attack HIV-infected cells. This research, published in the Journal of Clinical Investigation, focused on bolstering the body’s natural immune response. The current multi-cytokine scaffold approach complements this work by enhancing the longevity of the engineered CAR-T cells designed to target HIV.

Study Details and Limitations

The Science Advances study primarily involved experiments in mouse models. While these results are promising, it’s crucial to remember that findings in animal models don’t always translate directly to humans. The researchers demonstrated sustained control of human blood cancers and suppression of HIV infection in these models, but further research is needed to determine the safety and efficacy of this approach in human clinical trials. The study details do not specify the exact number of mice used or the specific types of blood cancers tested, highlighting a limitation in the publicly available information.

The multi-cytokine scaffold is a manufacturing approach, meaning it focuses on how the CAR-T cells are produced, rather than altering the cells themselves. This is a significant advantage, as it could potentially be applied to a wide range of CAR-T therapies targeting different cancers and infections. However, the long-term effects of the scaffold on the CAR-T cells and the patient’s immune system remain to be investigated.

NIH Funding and the Future of HIV Research

Research into HIV and AIDS continues to be a major priority for the National Institutes of Health (NIH). The Einstein-Rockefeller-CUNY-Mount Sinai Center for AIDS Research (ERCM-CFAR) is one of 20 Centers for AIDS Research (CFAR) funded by the NIH, receiving $44.5 million in funding from the Office of AIDS Research. Recent NIH funding policy changes, however, have presented challenges to HIV-related trial networks, potentially impacting the pace of research. The ERCM-CFAR involves over 160 investigators and has contributed to over 1,250 HIV/AIDS-related published papers.

What’s Next for CAR-T Cell Research?

The next steps involve rigorous preclinical testing to optimize the multi-cytokine scaffold and assess its safety profile. Researchers will need to determine the optimal combination of cytokines and the most effective way to deliver them to the CAR-T cells. If these studies are successful, the team plans to initiate human clinical trials to evaluate the efficacy of this approach in patients with cancer and HIV. These trials will be critical for determining whether the promising results seen in mouse models can be replicated in humans. The process of moving from preclinical research to clinical trials is lengthy and complex, requiring careful planning and regulatory approval.

Beyond clinical trials, ongoing research will focus on understanding the mechanisms by which the multi-cytokine scaffold enhances CAR-T cell persistence. This knowledge will be invaluable for developing even more effective immunotherapies in the future. The ultimate goal is to develop a curative therapy for HIV and to improve the outcomes for patients with cancer.